We highly recommend Opcon-A Allergy Eye Drops by Bausch + Lomb to anyone experiencing red, itchy, and irritated eyes due to allergies. Opcon-A Allergy Eye Drops are a great solution for anyone who ...
Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the NCX 470 ...
Young nearsighted kids who wear bifocal contact lenses that slow uncoordinated eye growth do not lose the benefits of the treatment once they stop wearing the lenses, new research shows.
"My patients appreciate being able to recycle their used eye health materials." Healthcare company keeps over 450,000 pounds ...
Vicks once again achieved the top monthly spot for TV impressions, while iSpot noted that pharma brands generated more year-over-year returns from sports and news cables compared to 2023.
Shares in ophthalmology specialist Bausch + Lomb (B+L ... the FT reports that Blackstone is likely to drop out of the consortium, reducing the chances of a deal going through.
Health scientists from the University of Virginia have found a previously unknown contributor to harmful blood vessel growth ...
Oculis' main value driver appears to be OCS-01, which targets a respectable $4B DME TAM with its non-invasive eye drops. See ...
InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...
The global vision care products market is projected to reach USD 103.7 billion by 2032, growing at a CAGR of 6.21%. This growth ...
City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...